Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Cardiovascular Disease: Personalized Medicine and Drug Management
share announcement

Cardiovascular Disease: Personalized Medicine and Drug Management

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".

Deadline for manuscript submissions: closed (5 November 2023) | Viewed by 983

Special Issue Editor

Dr. Prasanth Puthanveetil

E-Mail Website
Guest Editor
Department of Pharmacology, College of Graduate Studies, Midwestern University, Downers Grove, IL 60515, USA
Interests: metabolism; metabolic signaling; drug targets; immunopharmacology; infections; inflammation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cardiovascular diseases (CVDs) comprise the leading cause of mortality and morbidity globally. Despite the advances we have made in therapeutics, there are so many unmet needs in the area of cardiovascular medicine for various complications. These significant limitations are due to confounding factors such as other complications and their respective treatments overlapping with ongoing cardiovascular complications and due to the unique genetic makeup of everyone.

This Special Issue aims to shed light on the issues faced by patients suffering from cardiovascular complications due to the above-mentioned complications, focusing personalized medicine and adequate drug management to avoid associated health complications. Understanding in depth the genetics and disease profiling of each patient, alongside making a conscious decision to avoid significant drug–drug interactions and drug–diet interactions, can minimize complications and aid in faster recovery.

The current series highlights state-of-the-art research, including basic, translational, and clinical work focusing on personalized medicine approaches and findings on drug management to consciously avoid errors in treating cardiovascular disease.

We are delighted to accept manuscripts of original research (including communications) and review articles, focusing on basic translational and clinical studies providing detailed information and clearly defining the role of personalized medicine and drug management in controlling cardiovascular diseases.

Dr. Prasanth Puthanveetil
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiovascular disease
  • adverse drug effects
  • drug interactions
  • cardiovascular pharmacology
  • personalized medicine

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 2204 KiB  
Article
Investigation of the Therapeutic Potential of Organic Nitrates in Mortality Reduction Following Acute Myocardial Infarction in Hyperlipidemia Patients: A Population-Based Cohort Study
by An-Sheng Lee, Chung-Lieh Hung, Thung-Shen Lai and Ching-Hu Chung
J. Pers. Med. 2024, 14(1), 124; https://doi.org/10.3390/jpm14010124 - 22 Jan 2024
Viewed by 759
Abstract
Background: Dyslipidemia is a known risk factor for cardiac dysfunction, and lipid-lowering therapy with statins reduces symptoms and reduces hospitalization related to left ventricular heart failure. Acute myocardial infarction (AMI) is a cause of morbidity and mortality worldwide. In this study, we aimed [...] Read more.
Background: Dyslipidemia is a known risk factor for cardiac dysfunction, and lipid-lowering therapy with statins reduces symptoms and reduces hospitalization related to left ventricular heart failure. Acute myocardial infarction (AMI) is a cause of morbidity and mortality worldwide. In this study, we aimed to determine the real-world AMI treatment drug combination used in Taiwan by using the NHI database to understand the treatment outcomes of current clinical medications prescribed for hyperlipidemia patients with AMI. Methods: Using the NHI Research Database (NHIRD), we conducted a retrospective cohort study that compared different treatments for AMI in hyperlipidemia patients in the period from 2016 to 2018. We compared the survival outcomes between those treated with and without organic nitrates in this cohort. Results: We determined that most hyperlipidemia patients were aged 61–70 y (29.95–31.46% from 2016 to 2018), and the annual AMI risk in these patients was <1% (0.42–0.68% from 2016 to 2018). The majority of hyperlipidemia patients with AMI were women, and 25.64% were aged 61–70 y. Receiving organic nitrates was associated with lower all-cause mortality rates (HR, 95% CI, p-value = 0.714, 0.674–0.756, p < 0.0001). After multivariate analysis, the overall survival in four groups (beta-blockers, beta-blocker + diuretics, diuretics, and others) receiving an organic nitrate treatment was significantly higher than in the groups that were not treated with organic nitrates (beta-blockers HR = 0.536, beta-blocker + diuretics HR = 0.620, diuretics HR = 0.715, and others HR = 0.690). Conclusions: The survival benefit was significantly greater in patients treated with organic nitrates than in those treated without organic nitrates, especially when combined with diuretics. A combination of organic nitrates could be a better treatment option for hyperlipidemia patients with AMI. Full article
(This article belongs to the Special Issue Cardiovascular Disease: Personalized Medicine and Drug Management)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop